Real-World Treatment Trends Among Patients with Metastatic Castration-Sensitive Prostate Cancer: Results from an International Study.
Pedro C BarataAndrea LeithAmanda RibbandsRachel MontgomeryMatthew LastBhakti ArondekarJasmina IvanovaAlexander NiyazovPublished in: The oncologist (2023)
As the number of patients with mCSPC who receive treatment intensification increases, more patients who progress to metastatic castration-resistant prostate cancer (mCRPC) will have been exposed to intensified treatments. Treatment options for patients with mCSPC and mCRPC overlap, suggesting that an unmet need will emerge for new therapies. Further studies are needed to understand optimal treatment sequencing in mCSPC and mCRPC.